Is Viridian Therapeutics, Inc.\DE (VRDN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.8% / 30% | 30.2% / 30% | 0.0% / 30% | 38.67% / 5% | ✗ NOT HALAL |
| DJIM | 1.8% / 33% | 30.2% / 33% | 0.0% / 33% | 38.67% / 5% | ✗ NOT HALAL |
| MSCI | 5.6% / 33% | 97.2% / 33% | 0.0% / 33% | 38.67% / 5% | ✗ NOT HALAL |
| S&P | 1.8% / 33% | 30.2% / 33% | 0.0% / 33% | 38.67% / 5% | ✗ NOT HALAL |
| FTSE | 5.6% / 33% | 97.2% / 33% | 0.0% / 50% | 38.67% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -95643.2% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -49.2% | |
| Return on Assets (ROA) | -27.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$276M |
| Free Cash Flow | -$277M |
| Total Debt | $51M |
| Debt-to-Equity | 7.3 |
| Current Ratio | 12.6 |
| Total Assets | $899M |
Price & Trading
| Last Close | $28.20 |
| 50-Day MA | $29.82 |
| 200-Day MA | $24.39 |
| Avg Volume | 1.4M |
| Beta | 1.0 |
|
52-Week Range
$9.90
| |
About Viridian Therapeutics, Inc.\DE (VRDN)
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Viridian Therapeutics, Inc.\DE (VRDN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Viridian Therapeutics, Inc.\DE is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Viridian Therapeutics, Inc.\DE's debt ratio?
Viridian Therapeutics, Inc.\DE's debt ratio is 1.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.6%.
What are Viridian Therapeutics, Inc.\DE's key financial metrics?
Viridian Therapeutics, Inc.\DE has a market capitalization of $2.8B, and revenue of $71M. Return on equity stands at -49.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.